JP2005513000A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005513000A5 JP2005513000A5 JP2003541867A JP2003541867A JP2005513000A5 JP 2005513000 A5 JP2005513000 A5 JP 2005513000A5 JP 2003541867 A JP2003541867 A JP 2003541867A JP 2003541867 A JP2003541867 A JP 2003541867A JP 2005513000 A5 JP2005513000 A5 JP 2005513000A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- metastatic
- patient
- pharmaceutical composition
- psp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037819 metastatic cancer Diseases 0.000 claims 17
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 17
- 201000011510 cancer Diseases 0.000 claims 16
- 238000000034 method Methods 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 102100025142 Beta-microseminoprotein Human genes 0.000 claims 15
- 108010020169 beta-microseminoprotein Proteins 0.000 claims 15
- 102000043299 Parathyroid hormone-related Human genes 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 14
- 208000037147 Hypercalcaemia Diseases 0.000 claims 12
- 206010027476 Metastases Diseases 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 230000000148 hypercalcaemia Effects 0.000 claims 12
- 208000030915 hypercalcemia disease Diseases 0.000 claims 12
- 230000009401 metastasis Effects 0.000 claims 12
- 108700020797 Parathyroid Hormone-Related Proteins 0.000 claims 11
- 210000000988 bone and bone Anatomy 0.000 claims 10
- 230000001225 therapeutic effect Effects 0.000 claims 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 7
- 229910052791 calcium Inorganic materials 0.000 claims 7
- 239000011575 calcium Substances 0.000 claims 7
- 229940088597 hormone Drugs 0.000 claims 7
- 239000005556 hormone Substances 0.000 claims 7
- 206010060862 Prostate cancer Diseases 0.000 claims 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 6
- 230000001394 metastastic effect Effects 0.000 claims 5
- 206010061289 metastatic neoplasm Diseases 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 4
- 208000010658 metastatic prostate carcinoma Diseases 0.000 claims 4
- 208000006386 Bone Resorption Diseases 0.000 claims 3
- 206010027452 Metastases to bone Diseases 0.000 claims 3
- 101710123753 Parathyroid hormone-related protein Proteins 0.000 claims 3
- 230000024279 bone resorption Effects 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 2
- 206010050017 Lung cancer metastatic Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002361736A CA2361736A1 (en) | 2001-11-08 | 2001-11-08 | Psp 94: use for treatment of hypercalcemia and bone metastasis |
| PCT/CA2002/001737 WO2003039576A1 (en) | 2001-11-08 | 2002-11-08 | Psp-94: use for treatment of hypercalcemia and bone metastasis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005513000A JP2005513000A (ja) | 2005-05-12 |
| JP2005513000A5 true JP2005513000A5 (https=) | 2005-12-22 |
Family
ID=4170464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003541867A Pending JP2005513000A (ja) | 2001-11-08 | 2002-11-08 | Ｐｓｐ−９４：高カルシウム血症及び骨転移の治療のための使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20030119744A1 (https=) |
| EP (1) | EP1441756A1 (https=) |
| JP (1) | JP2005513000A (https=) |
| AU (1) | AU2002340681B2 (https=) |
| CA (1) | CA2361736A1 (https=) |
| WO (1) | WO2003039576A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050148514A1 (en) * | 2003-09-26 | 2005-07-07 | Panchal Chandra J. | Method and composition for treatment of angiogenesis |
| CA2441695A1 (en) * | 2003-09-26 | 2005-03-26 | Unknown | Regulation of matrix metalloproteinases by psp94 family members |
| JP2008501645A (ja) * | 2004-06-01 | 2008-01-24 | アンブリリア・バイオファーマ・インコーポレーテッド | 血管新生を治療し、癌の進行および転移を予防するための方法、ならびにそのための前立腺分泌タンパク質（ｐｓｐ９４）ファミリーメンバーを含む組成物 |
| CA2502479A1 (en) * | 2004-12-01 | 2006-06-01 | Procyon Biopharma Inc. | Laminin receptor binding molecule |
| JP2022536222A (ja) * | 2018-11-02 | 2022-08-15 | アンパサンド バイオファーマシューティカルズ インコーポレイテッド | 局所的に施用される緩衝液によるカチオン過負荷および電解質平衡異常のリスクの管理 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5428011A (en) * | 1992-06-16 | 1995-06-27 | Procyon Biopharma, Inc. | Pharmaceutical preparations for inhibiting tumours associated with prostate adenocarcinoma |
| CA2355334A1 (en) * | 2000-10-16 | 2002-04-16 | Procyon Biopharma Inc. | Pharmaceutical preparations and methods for inhibiting tumors |
| US20050026833A1 (en) * | 2001-11-08 | 2005-02-03 | Rabbani Shafaat Ahmed | PSP-94: use for treatment of hypercalcemia and bone metastasis |
-
2001
- 2001-11-08 CA CA002361736A patent/CA2361736A1/en not_active Abandoned
-
2002
- 2002-11-08 EP EP02774221A patent/EP1441756A1/en not_active Withdrawn
- 2002-11-08 US US10/291,360 patent/US20030119744A1/en not_active Abandoned
- 2002-11-08 WO PCT/CA2002/001737 patent/WO2003039576A1/en not_active Ceased
- 2002-11-08 AU AU2002340681A patent/AU2002340681B2/en not_active Ceased
- 2002-11-08 JP JP2003541867A patent/JP2005513000A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yang et al. | MicroRNA‐26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin‐6‐Stat3 pathway | |
| US20190360056A1 (en) | Fusion genes associated with progressive prostate cancer | |
| NO2017019I2 (no) | Enzalutamid eller et farmasøytisk akseptabelt salt derav | |
| RU2008130963A (ru) | Лечение метастатического рака молочной железы | |
| WO2008008315A3 (en) | Compositions and methods for inhibiting growth of smad4-deficient cancers | |
| EP3962559B1 (en) | Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues | |
| EA201200329A2 (ru) | Ингибиторы мет для повышения эффективности лучевой терапии | |
| MXPA05005545A (es) | Peptidos que se dirigen a celulas tomurales y endoteliales, composiciones y usos de los mismos. | |
| JP2005513000A5 (https=) | ||
| WO2008134752A3 (en) | Methods and compositions for the treatment of cancer | |
| He et al. | Golgi phosphoprotein 3 promotes malignant phenotypes via FAK/Raf/MEK and Wnt/β-catenin signaling pathways in human renal cell carcinoma | |
| IL164783A0 (en) | Epothilone derivative for the treatment or hepatoma and other cancer diseases | |
| Feng et al. | Clinicopathological features, management and outcome of patients with poorly-differentiated oral and oropharyngeal squamous cell carcinoma | |
| WO2014185528A1 (ja) | Ｔｋ１タンパク質の発現が亢進した結腸直腸癌患者に対する治療効果予測方法 | |
| Pinheiro et al. | Targeting metabolic reprogramming as an anti-cancer strategy: aiming at monocarboxylate transporters | |
| Zhu et al. | HNRNPC reprograms cancer metabolism to drive acquired chemoresistance in colorectal cancer by repressing of Nrf2/SLC7A11-dependent ferroptosis | |
| CN116287275A (zh) | Ptgr1作为cdk4/6抑制剂与二甲双胍联合用药指导标志物的应用 | |
| Beheshtizadeh et al. | Analysis of G3BP1 and VEZT expression in gastric cancer and their possible correlation with tumor clinicopathological factors | |
| WO2018098804A1 (zh) | 含有亚铁氨基酸螯合物的组合物用于制造防止癌症转移的医药品的用途 | |
| EA200601471A1 (ru) | Ингибиторы клеточной пролиферации клеток (варианты), фармацевтическая композиция на их основе, способ уничтожения раковых клеток (варианты) и способ лечения и профилактики злокачественных состояний (варианты) | |
| CN111748625B (zh) | miR-515-3p作为食管癌分子标志物的治疗应用 | |
| WO2006029406A3 (en) | Methods for treating bone tumors using bone morphogenic proteins | |
| Yournita et al. | Lymph Nodes Metastasis is Associated with Higher Body Mass Index in Indonesian Breast Cancer Patients | |
| Karaca et al. | 98P octreotide in combination with docetaxel triggers apoptosis by inducing Sstr2 and Sstr5 levels in human breast cancer cells, mcf-7 and mda-mb-231 | |
| Gu et al. | P3. 03-23 A Propensity Score Matching Cohort Study on Prognosis of the Diversity of MUC1 Expression in Patients with Lung Adenocarcinoma |